| abstract |
The disclosure relates to solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione represented by structural formula (I), compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. These solid forms are suitable for treating and/or preventing disorders ameliorated by the reduction of levels of TNF-a or the inhibition of PDE4. |